A safety update on sodium glucose co-transporter 2 inhibitors
States worry about being too stringent for fear of taking away jobs, but the FDA cant possibly oversee thousands of compounding pharmacies alone, she said
[11] [12] Patients with pre-existing gallstones discovered incidentally before starting GLP-1 therapy should discuss the risks and benefits with their healthcare provider, as the presence of asymptomatic gallstones is not necessarily a contraindication to treatment
Understanding your genetic predispositions alongside tirzepatide's mechanism empowers you to advocate for personalized dosing strategies and realistic outcome expectations
Research shows that GLP-1 receptor agonists like semaglutide also change how the intestines absorb nutrients and water
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
